1. Updates in Follicular Lymphoma

2. Learning Objectives

3. Follicular Lymphoma: Background and Demographics

4. WHO/REAL Grading of Follicular Lymphoma

5. Follicular Lymphoma International Prognostic Index (FLIPI)

6. FLIPI2

7. m7 FLIPI

8. Utility of PET and PET/CT in Follicular Lymphoma

9. NCCN Guidelines: First Line for Advanced Stage Follicular Lymphoma

10. Studies of Up-Front Treatment of Follicular Lymphoma

11. FOLL05 Study: Study Design and Outcomes

12. StiL Study: Bendamustine Plus Rituximab vs R-CHOP

13. BRIGHT Study: Bendamustine Plus Rituximab vs R-CHOP/R-CVP

14. PRIMA Study: Rituximab Maintenance vs Observation

15. FIT: 90Y-Ibritumomab Tiuxetan Consolidation vs Observation

16. The ZAR Study: Consolidation 90Y-Ibritumomab Tiuxetan vs Rituximab Maintenance

17. RESORT Study: Rituximab Maintenance vs Retreatment at Disease Progression

18. NCCN Guidelines: Relapsed FL

19. Phase 2 Study of R2 in Follicular Lymphoma: Study Design (MDACC)

20. R2 in Follicular Lymphoma: Outcomes

21. Alliance Trial: Rituximab Plus Lenalidomide in Follicular Lymphoma

22. Ibrutinib: Efficacy in FL Patients

23. Idelalisib: Phase 2 in Refractory iNHL

24. Obinutuzumab in CD20+ in Relapsed and/or Refractory FL

25. Venetoclax in Relapsed/Refractory FL

26. Personalized Treatment in Follicular Lymphoma

27. Abbreviations

28. Abbreviations (cont)

29. References

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)